抗血管内皮生长因子药物治疗脉络膜新生血管性疾病临床研究应注意的几个问题  

Issues raised in clinical researches using anti-vascular endothelial growth factor drugs to treat choroidal neovascularization

作　　者：戴虹[1] 

机构地区：[1]卫生部北京医院眼科,100730

出　　处：《中华眼底病杂志》2011年第6期503-505,共3页Chinese Journal of Ocular Fundus Diseases

摘　　要：抗血管内皮生长因子（VEGF）药物是治疗脉络膜新生血管（CNV）性疾病的首选方法，其疗效、安全性已为大量临床实践和循证医学研究所证实。但不同CNV病变的治疗原则、抗VEGF药物的最佳给药方案、联合治疗的适应证与方法、影响疗效的因素以及全身和局部潜在风险等诸多方面仍需探讨、完善和达成共识。如何根据患者自身情况制定合理的个体化治疗方案，是抗VEGF药物临床应用中亟需解决的问题。我们应当把握ranibizumab（商品名Lucentis）即将在国内上市的契机，在现有的循证医学研究结果基础上，利用我们病例资源丰富的优势，高起点的进行此领域的探索，以进一步推动我国抗VEGF药物临床应用研究水平的提高。Anti-vascular endothelial growth factor （VEGF） drugs have become the first-line medications for the treatment of choroidal neovascularization （CNV）. Its efficacy and safety have been confirmed by evidence-based medicine and a large number of clinical studies. However there are several issues need to be discussed before reaching a consensus for the clinical application of anti-VEGF drugs. These issues include, but not limited to the individual treatment regimen for different CNV lesions, the best anti-VEGF drug regimen, the indications and schemes of combination therapy, the factors affecting the efficacy, the potential risks of systemic and local deliveries. How to establish a reasonable personalized regimen of anti-VEGF drugs is the 1st issue need to be explored. Ranibizumab will come into China market soon. We need utilize the existing evidence-based medical research findings; take our advantages of rich resources of patients to investigate those issues to further promote the anti-VEGF applications in China.

关 键 词：脉络膜新生血管化/治疗 血管内皮生长因子类 述评 

分 类 号：R774.1[医药卫生—眼科] R773.4[医药卫生—临床医学]